Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

# Preparation of iron oxide mesoporous magnetic microparticles as novel multidrug carriers for synergistic anticancer therapy and deep tumor penetration

## Abstract

The preparation of mesoporous iron oxides with controllable physiochemical properties for effective therapeutic drug delivery remains a formidable challenge. Herein, iron oxide mesoporous magnetic microparticles (IO-MMMs) were prepared by a modified reverse hard-templating approach using, for the first time, acid-prepared mesoporous spheres (APMS) as the hard silica template. The obtained mesostructures exhibited remarkably high surface area and large pore volumes (SBET = 240 m2/g and Vpore = 0.55 cm3/g), controllable average sizes, generally uniform morphologies, and excellent biocompatibilities, allowing them to achieve optimal drug release in cancer cells and tumor tissues. IO-MMM carriers were able to co-load high amounts of hydrophilic chemotherapeutic drugs (Dox or Daun) and/or hydrophobic hormonal anticancer drugs (Tam), and release them sustainably in a pH-dependent manner, utilizing the fluorescence of Daun to real-time trace the intracellular drug distribution, and employing Daun/Tam to treat cancer by combined chemo/hormonal therapy. Cytotoxicity assays against different types of cancerous cells showed that the combinatory Daun/Tam@IO-MMM formulation significantly reduced the viability of metastatic MCF7 and KAIMRC1 breast as well as HCT8 colorectal cancer cells, with the least potency towards non-cancerous normal primary cells (up to 10-fold). Electron, flow, and live confocal microscopy imaging confirmed that the loaded vehicles were successfully and differentially uptaken by the different tested cells, gradually releasing their payloads, and causing apoptotic cell death. Importantly, compared to free drugs, Daun/Tam@IO-MMMs displayed enhanced drug accumulation in patient breast primary tumor tissues, deeply penetrating into the tumor region and killing the tumor cells inside. The designed carriers described here, thus, constitute a novel promising magnetic mesoporous smart system that entraps different kinds of drugs and release them in a controlled manner for combinatorial chemo/hormonal cancer theranostics. This multifactorial platform may open new avenues in cancer therapy as efficient synergistic antitumor system through overcoming limitations of conventional cancer therapy.

## Introduction

Cancer therapy is a long-standing, formidable and complex process1. In most cases, single strategy such as chemotherapy, hormonal therapy, photothermal therapy, or immunotherapy alone is not sufficient to eradicate and eliminate tumors completely. The major challenge remains to establish an advanced carrier platform that can efficiently and selectively destroy cancer cells and penetrate deeply into tumor tissues, releasing their therapeutic payloadsin a controlled manner2,3,4,5. Consequently, examples of advanced drug delivery systems with chemo/photodynamic, immuno/photothermal, or chemo/immuno therapeutic combinations have been recently investigated with promising potentialsin cancer treatment6,7,8. Despite the many obstacles, however, developing formulations with controlled drug release and synergistic combination therapy can be the optimal strategy for intratumoural drug delivery and enhanced cancer therapeutics.

Of the various drug delivery systems established9,10, mesoporous (having pores of 2 to 50 nm) platforms are especially attractive, due to their large surface areas, internal pore volumes, and tunable pore structures allowing large amounts of various drugs to be loaded into their pores at once and subsequently released on demand. Besides, when the construct is further magnetic, the obtained particles will have potential promise in medicine particularly as magneto-responsive drug delivery carriers11. In fact, hybrid mesoporous and/or magnetic carriers are gaining immense importance in improving cancer therapies systematically explored in oncology12,13. In this context, materials that respond to intracellular pH-driven stimulus have shown to perfectly implement excellent spatial, temporal, and dosage control drug release from different types of carriers with reduced side toxicities, thus, enhancing the efficacy of therapies14,15,16. Consequently, a pH-susceptible iron oxide-based mesoporous material, which is both magnetic and porous, employed as synergistic antitumor platform for cancer therapy is highly desirable. Nonetheless, the impeccable means to synthesize high-quality mesoporous magnetic iron oxide materials with large surface areas and pore volumes remains unambiguously challenging. Thus, preparation of mesoporous iron oxides with controllable physiochemical properties for drug delivery applications is not well established and is explored to less extent. In fact, most mesoporous-based drug delivery systems focus either on mesoporous silica materials or hetero-structured materials, particularly composed of magnetic iron oxide nanoparticles (MNPs) coated with mesoporous silica shells (core/shell), loaded into hollow mesoporous silica nanosphere, or embedded in a mesoporous silica matrix17,18,19,20,21,22. Reports on the utilization of mesoporous iron oxide nano/microstructures for therapeutic drug delivery applications are very rare23,24,25. Importantly, according to our knowledge, mutli-drug delivery using mesoporous magnetic constructs to deliver combination of both hydrophilic and hydrophobic anticancer therapeutic drugs simultaneously has not been reported.

The formation of mesoporous silica, alumino-silicates and related materials are well-known and relies on supramolecular arrays: micellar systems formed by anionic or cationic surfactants26 or block copolymers (mainlypolyethylene-based polymers)27. However, the synthesis of porous transition metal oxides, particularly iron oxides, has proven to be significantly more difficult and limited28, with some important advances seen in recent decades29. In general, other than the less used solvothermal or hydrothermal methods which results in very poor porous materials24,30,31,32, mesoporous metal oxide materials are most commonly prepared either via “soft-templating method” (templated by surfactants, block copolymers, colloids etc.)33,34,35,36 or by the “hard-templating method” (i.e. guest materials replicate the “inverse” or “surface” structures of the “host” inorganic materials), where an inverse replica is produced37,38,39,40. Utilization of hard templates for the preparation of mesoporous metal oxides has some advantages compared with soft templates, especially in its specific topological stability, veracity, predictability, controllability, and crystalline properties41. From the various hard templates employed (i.e. alumina membranes, latex spheres, carbon nanotubes, carbon-silica composites etc.), mesoporous silica has already displayed its power to incorporate different guests into their matrices, which led to fabrication of a great variety of nanostructured composites, such as carbon42, transition metals43, and metal oxides39,44,45,46,47. Particularly, three-dimensional (3D) and two-dimensional (2D) mesoporous silica (i.e. KIT-6, SBA-15, MSU-H, MCM-41 etc.) with ordered or disordered mesopores and high internal pore surface area have proven to be an ideal host for the syntheses of such materials48,49,50,51,52. Moreover, their thermal stability and high silanol density helps to incorporate inorganic metal precursors into their channels by sorption, phase transition, ion exchange, or grafting and, thus, form an inorganic framework by further thermal treatments. For instance, solutions of iron salts (i.e. FeCl3or Fe(NO3)3) are typically used as precursors that are either co-precipitated with the silica source or infiltrated into porous silica53,54. The subsequent drying and thermal treatment results in distribution of iron oxide nanoparticles inside the silica matrix, followed by final etching of the silica template to form the desired material. Using this nanocasting templated approach, mesoporous iron oxides(Fe2O3or Fe3O4) with ordered and disordered crystalline walls have been prepared via impregnation of different iron concentrations into calcined mesostructured silica templates, mainly 3D bicontinuous KIT-6and 2D hexagonally ordered SBA-1541,48,51,55,56. However, low surface areas and pore volumes are typically obtained. General challenges in quick crystallization, accompanied with structural collapse during the mesostructure formations, along with the nature of the pore structures within the micellar silica template chosen are considerable issues. Other difficulties lie in the removal of the silica template, where the replicated mesostructure is seldom maintained because the inorganic precursors are inclined to be absorbed on the external surface of templates or the channels are not completely filled, causing the framework formed inside the pores to be lacking in sufficient internal cross-linkages51,57.

In this work, we report the preparation of iron oxide mesoporous magnetic microparticles (IO-MMMs) with high surface areas and large internal pore volumes based on a modified reverse hard-templating approach using a novel mesoporous silica as the host. In particular, acid-prepared mesoporous spheres (APMS) are employed for the first time as the hard silica templates. Because of the excellent properties of the APMS template resulting from its rigid framework, 3D interconnected pores, as well as its high chemical and thermal stability, good control over key physiochemical properties of the replicated material is achieved. The as-prepared IO-MMMs exhibit generally spherical shapes, uniform size distributions, high surface areas, and large pore volumes, allowing them to be utilized as efficient multi-drug delivery vehicles. In order to achieve maximal synergistic anticancer effects, co-loading high amounts of one or more therapeutic drug is a necessity to attain simultaneous drug delivery with optimal efficient doses. As a proof-of-concept, anticancer chemo/hormonal therapeutic drugs of various hydrophilicities were loaded into the IO-MMMs and systematically tested against different types of human cancerous cells and patient tumor tissues. Loading and release results show that high loading efficiencies were achieved with drug release rates dramatically improved at low acidic cellular pH, but not at neutral physiological pH. The cytotoxic effects of IO-MMMs and drug@IO-MMMs were then evaluated in different types of breast and colorectal cancer cells as well as normal primary cells. The fluorescence of drugs was monitored by live confocal imaging to demonstrate subcellular internalization and pH-driven drug release of drug@IO-MMMs inside the cells. Moreover, electron microscopy was employed to further assess the uptake of the IO-MMMs-treated cellular samples. Importantly, when tested with primary breast tumor surgery sections derived directly from patient primary lesions, enhanced drug penetration with evident tissue shrinkage was observed, implying that the system is a highly promising combinatory chemo/hormonal therapeutic platform with efficient synergistic antitumor effects. This new platform designed here integrated real-time tracking, pH-driven drug release, and chemo/hormonal therapy, affording optimized efficacy to potentially treat cancer through enhanced passive targeting and combinatorial therapeutic mechanisms. To our knowledge, this is the first report using chemo/hormonal magnetic formulation to systematically study the microparticles’ uptake and co-delivery of their cytotoxic agents to different types and stages of human cancerous cells and tumors.

## Results and Discussion

### Preparation and characterization of IO-MMMs

Fabrication of IO-MMMs was achieved based on a modified reverse hard-templating nanocasting methodology as outlined in Fig. 1. The first steps involve the production of the hard silica APMS template containing unique 3D pore-connected network and average pore size diameters of ~ 4–6 nm prepared according to our previous work58,59. In situ reduction of iron(III) precursors during impregnation process, followed by thermal treatment under an inert atmosphere, and finally removal of the silica template generated the desired mesoporous material. In particular, iterative incorporation of APMS silica by aqueous solutions of iron (III) salt (i.e. FeCl3) in the presence of a reducing agent, followed by a thermal sintering step produced the continuous iron oxide phase within the pores. Treatment with basic NaOH solution etched away the silica template affording IO-MMM constructs. Repeated impregnation allows maximal incorporation of the aggregated iron precursors filling the continuous mesopore system, which are turned to spherical iron oxide nanoclusters within the silica template during the reduction and heating treatments.

The as-prepared IO-MMM mesoconstructs were thoroughly characterized by different spectroscopic techniques including scanning and transmission electron microscopy (SEM and TEM), energy-dispersive X-ray spectroscopy (EDX), nitrogen (N2) physisorption porosimetry, X-ray diffraction (XRD), fourier-transform infrared (FTIR), and dynamic light scattering (DLS). SEM images of the APMS silica host, the APMS-IO intermediate, and the templated IO-MMMs at different magnifications are shown in Fig. 2a–c. Typical average APMS sizes of ~1.5 μm with a spherical morphology and practically uniform distribution was observed. While the surface of APMS seem to be clear, smooth, and free of surface cracks, APMS-IO intermediate appeared as IO-dotted architectures, and the final IO-MMM exhibited porous bumpy-like structures. EDX elemental analysis performed on selected SEM areas confirmed the presence of only Fe and O without any other element as impurity in the final replicated mesoporous material (Fig. 2d). EDX measurements on the intermediate samples reveal average atomic Fe/Si ratios of 0.5:1 corresponding to almost equal weight percentages of Fe to Si. This range fits with the relative iron quantities used for impregnation, indicating that iron is distributed quite homogeneously within the samples. FTIR spectroscopy for IO-MMMs clearly showed the distinctive characteristic absorption stretching bands of iron oxide Fe-O (~500–600 cm−1) and O-H (~3200–3600 cm−1), with the disappearance of peaks in the region 960–1100 cm−1 correspondingto Si-O (1100 cm−1) and Si-O-Fe (960 cm−1) stretching vibrations60 (Fig. 2e), confirming the EDX results. TEM images were then recorded to identify the mesostructure of the obtained IO-MMMs (Supplemental Fig. S1). From a TEM image of a single particle, it is clearly indicated that the original mesopore APMS system has been replicated and that the obtained material is composed of interconnected small nanoparticles that possess mesopores (Fig. 3a–c). For APMS-IO intermediate and due to the electronic density contrast, iron oxide nanoclusters (in black) appear to be homogeneously distributed within the mesopores of APMS (in gray) (Fig. 3b). Very few agglomerated iron oxide species were observed independently, suggesting that the impregnation occurred mostly inside the mesopores. In Fig. 3c, the light-contrast areas randomly distributed throughout the microparticle indicate the presence of replicated disordered interconnected porous network and also display the crystallinity of the IO-MMM framework. To further explore the phases and crystalline nature of IO-MMMs, wide-angle powder XRD was performed. XRD data revealed that the produced brown-colored material is γ-Fe2O3 (maghemite), with observed diffraction patterns in excellent agreement with previously published data for maghemite (JCPDS #039-1346)39,61,62 (Fig. 3d). A d-value of 2.96 Å corresponding to the spacing of (220) planes confirmed the presence maghemite63. The diffraction peaks are quite low in intensity, signifying that the mesoporous walls are composed of crystalline framework. Most imperious, the porous nature of IO-MMMs was examined by N2 adsorption/desorption experiments. As shown in Fig. 3e, successive iron loading (i.e. repetitive iron-impregnation to ensure maximal loading) indicated significant decrease in the surface area and pore volume of APMS-IO compared to the original calcined APMS silica host having Brunauer-Emmett-Teller surface area (SBET) = 625 m2/g and pore volume (Vpore) = 0.85 cm3/g, both indications of iron oxide incorporation/coating of the inner pore surfaces of the silica walls. The pore size distribution plots revealed a quitesharp average pore diameters (dpore) centered at ~5 nm (Fig. 3e inset). Remarkably, N2 physisorption isotherm of the final replicated IO-MMM (after thermal treatment and etching) showed that the obtained mesostructured iron oxides exhibit relatively high SBET of 240 m2/g and Vpore of 0.55 cm3/g, with broad pore-size distribution having a major dpore at ~ 4 nm (Fig. 3f). The isotherm demonstrates a typical Type IV curve characteristic with a well-defined hysteresis loop, indicative of the presence of mesopores and consistent with the recently reported porosities for mesoporous iron oxides48. Because of the disorder interconnected nature of channels in APMS, the pore size distribution of the product is somehow broad as a result of random growth and orientation of iron oxide crystals within the APMS template during impregnations and subsequent thermal treatments. The obtained pore-size distributions, however, are in good agreement with the pore diameters anticipated for a replica structure of APMS. According to our knowledge, the as-prepared IO-MMMs obtained here have higher surface areas than any other mesoporous iron oxide material reported in the literature, which is typically between 86 to 187 m2/g48,51,61,63.

Hydrodynamic particle sizes and zeta potentials were then measured by DLS (Fig. 4a,b). Aqueous dispersion of IO-MMM in water depicted an average hydrodynamic size (DH) = 765 nm which is approximately two fold smaller than the average DH (~1500 nm) for APMS. This is expected and agrees well with the N2 physisorption results, as replicated mesoporous materials should typically have smaller sizes than their templates. The relatively sharp peaks obtained further confirms the core size obtained by electron microscopy and pinpoints the uniform size distribution and stable dispersity of the as-synthesized IO-MMMs (PDI ~0.5) in water. As expected, the intermediate APMS-IO revealed similar hydrodynamic sizes compared to APMS, suggesting major deposition of iron oxide nanoclusters inside the pores. However, a smaller population at ~190 nm corresponding to 20% of the total intensity was observeddue to iron oxide agglomerates forming independently outside the pores, consistent with TEM results. Notably, zeta potential measurements indicated average zeta potential (ξ) = −12.03 ± 4.62 mV for APMS template, ξ = −45.35 ± 3.07 mV for intermediate APMS-IO, and ξ = −32.5 ± 1.87 mV for IO-MMM, further corroborating successful incorporation of iron oxide and etching of the silica template. All these data combined suggest the assured formation of high surface area and large pore volume IO-MMM mesostructures. Moreover, the high density of hydroxyl groups on IO-MMM surfaces render them water dispersible and suitable for biological assays.

It is worth pinpointing that we initially attempted synthesizing the iron oxide mesoporous constructs by incipient wetting of the APMS template via polyacrylic acid-stabilized iron oxide MNPs (PAA-MNPs). Taken into account the strong chelating effect of PAA to the iron oxide surfaces and its previous successful use in the formation of mesoporous iron oxide nanospheres23, we thought this will be an effective approach to prepare IO-MMMs. PAA-MNPs were synthesized using our “Ko-precipitation Hydrolytic Basic (KHB)” methodology64,65 resulting in uniform, stable, and colloidal ultrasmall MNPs of ~5 nm core diameter. APMS was then impregnated with PAA-MNPs, followed by thermal treatment to facilitate decomposition of PAA polymer and fusion of IONPs. However, it seems that the pore diameters of APMS template are not able to host PAA-MNPs which appear to mainly cluster and aggregate on the APMS surface rather than fill the pores. Nevertheless, TEM and N2 physisoprtion isotherms confirmed the presence of some iron oxide mesoporous magnetic nanoclusters (IO-MMNs) with lower surface areas (SBET = 88.6 m2/g and Vpore = 0.157 cm3/g) and smaller hydrodynamic sizes ~300 nm (Supplemental Fig. S2).

### Magnetic behavior of IO-MMMs

Due to the intrinsic magnetic properties of iron oxide, one of the key advantages of the designed IO-MMMs is their potential use as magnetic imaging probes, magnetically-triggered drug delivery, and clinical hyperthermia11,19,25. Magnetic resonance imaging has become the ideal imaging modality to test the biodistibution of magnetically-labeled cells and monitor their fates noninvasively. Furthermore, human tissues are transparent to magnetic field, making the use of external magnet an alternative and powerful approach to overcome limitations of light-enhanced or photo-responsive drug delivery. It was found that IO-MMMs can be easily separated by a magnetic force from their water dispersions within a few minutes, signifying the magnetic characteristics of the mesostructures (Fig. 4c). Furthermore, to test the capabilities of IO-MMMs to label cells, we measured the response of IO-MMM-tagged cells to a static magnetic field. As a proof of principle, KAIMRC1 cells were incubated with IO-MMMs, harvested, and transferred to petri dishes, one of which was located within a static magnetic field (Fig. 4c). Delightfully, it was clear that in the presence of the magnet, cells were concentrated and aligned with respect to the magnetic field lines while in the absence of the permanent magnet, cells were rather disseminated in the petri dish. This demonstrates the possibility of concentrating and spatially locating IO-MMM-tagged cells which is particularly useful for applications such as magnetic cell sorting. This magnetic IO-MMM platform may open new opportunities as promising materials not only for combined chemo/hormonal therapy but also for magnetically-triggered hyperthermia drug delivery applications.

With the drug@IO-MMMs in hand, we first investigated their in vitro drug release profiles in PBS buffer at two different pH values (Fig. 5c). Release of drugs from the IO-MMM mesostructures was found to be pH-dependent, allowing the drugs to be selectively released within the slightly acidic environments, but not at physiological neutral conditions. The total drugs released from IO-MMM constructs were about 40% Dox, 50% Daun, and 80% Tam at slightly acidic pH of 4.5 after 48 hrs, which is remarkably higher than that at physiological pH of 7.4 (only 7–10% after 48 hrs). In the case of the hydrophobic drug Tam, faster release at low acidic pH was observed compared to a more sustained Dox and Daun release, which might be ascribed to the physical absorption of the drugs inside the nanochannels. The initial burst release in the first hours is typical and is attributed to the rapid diffusion of drug molecules which interact weakly with the outer surfaces or near the pore entrances of the channels. From the release studies, it is evident that at neutral pH the drugs are tightly captured within the large surface areas of IO-MMM pores mainly due to electrostatic, hydrogen bonding, and van der Waals interactions between the drug molecules and particle/pore surfaces containing large number of hydroxyl groups. Due to the protonation of the hydroxyl groups on IO-MMM with the decrease in pH, electrostatic interactions between drugs and IO-MMM will be decreased, causing their release from the IO-MMM surface and mesoporous channels (Supplemental Fig. S5), consistent with previous observations19,75. For instance, Dox (pKa = 8.25) is positively charged at neutral pH76 and can be adsorbed onto the negatively charged IO-MMMs. Meanwhile, hydrogen bonding between the hydroxyl groups of IO-MMM and the corresponding groups of Dox could be disrupted by adjusting proton amounts at different pH values30,76,77,78. A recent report attributed that Dox release at lower pH is due to the competitive binding of hydronium ions (H3O+) to the pores of mesoporous iron oxide25. Moreover, it has been shown that the coordination between Dox and Fe(III) is more labile at acidic pH, which is also consistent with the observed release at lower pH79. All this proves that the drug release is faster at mildly acidic pH values as a consequence of the overall weakened interactions between the drugs and the particle/pore surfaces. This contained drugs at neutral pH with higher but smoother release rates at low pH is especially beneficial for combination therapeutic drug delivery, where the acidic environment in the tumor tissues and late endosomes/lysosomes in cells facilities drug release from IO-MMMs, while the release in blood and other normal tissues are slow reducing unwanted side effects. Furthermore, the initial burst release of drugs is preferable to achieve a sufficient initial drug dosage in tumor treatment, with the sustained release necessary to prevent further cancer proliferation. Similar pH-dependent drug release profiles with various nanomedicines have demonstrated better therapeutic and antitumor effectiveness in delivering chemotherapeutic drugs when tested both in vitro and in vivo19,76,78,80. It is worth pinpointing that particles where drug molecules are covalently conjugated to their surfaces usually exhibit much lower drug loading efficiencies and more difficulty in drug release due to the covalent binding. Thus, the prepared drug@IO-MMMs with the high drug payload capacity and the excellent pH-dependent drug release properties, are both essential requirements to attain a notable level of therapeutic dose at the target cancerous cells and tumor tissues, resulting in effective cancer therapy.

### Biological and cytotoxicity assays

The cytotoxic effects of IO-MMM and drug@IO-MMM formulations towards different types of human breast (MCF7 and KAIMRC1) and colorectal (HCT8) cancerous cells, as well as normal primary cells were then examined using the thiazolyl blue tetrazolium bromide (MTT) cell viability assay. First to demonstrate the potential utility of IO-MMMs as biocompatible delivery vehicles, the as-prepared IO-MMMs were tested against the different cancerous cells. IO-MMMs elicited no cytotoxic effects to any of the tested cells, even at high concentrations up to 100 µg/mL particles (Fig. 6a). Importantly, the different drug-loaded IO-MMM formulations (30 µg/mL particles; 7.5 µg/mL for Dox or Daun and 5.25 µg/mL Tam) were found to be highly toxic to MCF7 and KAIMRC1 breast cancer cells as well as to HCT8 colorectal, with the least potency towards the normal primary cells (Fig. 6b). Interestingly, the combinatory Daun/Tam@IO-MMM formulation showed the most potent effects on the different cancerous cells tested with 10-fold and 5-fold enhanced cytotoxicities against the metastatic breast cancer and colorectal cancer cells in comparison to normal cells, respectively. It is anticipated that upon internalization, IO-MMMs release both Daun and Tam inside the cells, and, hence, enhance the cytotoxic effect through exhibiting synergistic anti-proliferative activities on the different cancerous cell lines. On the other hand, the free drugs, at equivalent concentrations, were found to be concurrently toxic to all the tested cells. This is in agreement with our previously published reports72,81. While the potency of drug@IO-MMMs towards the different cancerous cell lines was comparable to the potency of free drugs, it significantly decreased against the normal primary cells. This observed enhanced cytotoxicities of drug@IO-MMMs compared to free drugs towards cancerous cells, with the least sensitivity towards the normal cells suggest huge potentials for IO-MMMs as efficient and selective drug delivery vehicles.

To explore the route and intracellular drug delivery of the drug@IO-MMM constructs to the different cell lines, confocal laser scanning microscopy (CLSM) was performed. To mimic physiological conditions, live confocal imaging with no fixation of cells was conducted. We treated two different types of cancerous cells (i.e. colorectal HCT8 and breast KAIMRC1) along with primary normal cells with IO-MMMs, Daun/Tam@IO-MMMs or equivalent concentrations of the respective free drugs. All the cells treated with control IO-MMMs appear healthy with clear blue Hoechst nuclei stains and no apoptotic features or death observed (Supplemental Fig. S6). In the drug-treated cells, however,the distribution of the red Daun fluorescence showed a pattern that varied for the different cells exposed to free Daun/Tam vs Daun/Tam@IO-MMMs. In Daun/Tam@IO-MMMs-treated cancerous cells, confocal images confirmed that Daun delivered by Daun/Tam@IO-MMMs is entering the cells gradually as time elapses causing apoptotic cell death after 24 hrs (Fig. 7). The intensity of red fluorescence increased progressively in cells with incubation time, resulting from the sustained drug release property of drug@IO-MMMs. While typical apoptotic features were clearly evident for HCT8 and KAIMRC1 cells, the primary cells appeared to be healthy even after 24 hrs of treatment. Head-to-head comparison between the three cell lines treated with Daun/Tam@IO-MMMs after 24 hrs showed that Daun was translocated to the nucleus in cancerous cells, with more killing observed for HCT8 compared to KAIMRC1 cells, confirming the cell viability cytotoxicity results (Fig. 7a,b). On the other hand, normal primary cells showed the least florescence intensities, where Daun was found to be mainly in the cytoplasm, with no prominent red nuclear staining or apoptotic features detected (Fig. 7c). Importantly, when incubating the same cell lines with free Daun/Tam at equivalent concentrations, the red fluorescence was found to be directly localized in the nucleus of all cells concurrently with minimal detectable presence in the cytoplasm, even after only 6 hrs of incubation.

### Cellular internalization of IO-MMMs

Next, in order to gain insights into how the IO-MMMs interacted with the cells, their uptake with the different tested cell lines was examined by flow cytometry. Upon incubation of the cells with fluorescent-labeled IO-MMMs (10 μg/mL), all cell types showed significant cellular uptake gradually increasing with time, but slowly declining after 24 hrs (Fig. 7d). Interestingly, the fluorescence signals of cancerous cells demonstrated an uptake approximately 7-fold and 4-fold higher at 2 hrs and 24 hrs of incubation, respectively, compared to the primary normal cells with the least uptake. This confirmed and explained the confocal microscopy results obtained. Our findings are consistent with the results of previous studies by us72,73 and others82,83, reporting on the increased uptake of IONPs by human breast, leukemia and cervical cancer cells compared to normal cells. While this definitely requires further mechanistic studies, it is mostly attributed to the variations in cell-membrane compositions, characteristics, morphologies, immunoprofiles, and metabolic activities between the tested cancerous and normal cells82,83,84,85. The high metabolic activity of tumor cells along with the low metabolic activity of primary normal cells can particularly contributes to the observed increase in IO-MMMs’ uptake. Even when the normal primary cells grew in culture dish, they acquire much more time to confluent with double the amounts of growth factors added.

To further verify the uptake of the IO-MMM-treated cells at the sub-cellular level, the intracellular distribution was evaluated by electron microscopy imaging. SEM images clearly indicate that the tested cells uptake the particles mainly found to be attached to the cellular membranes and consequently internalized inside (Fig. 8a). Some IO-MMMs were found to be located on the periphery of the cells attached to their surfaces (Fig. 8b). However, wrapping of the cellular membrane around the particles is clearly evident (Fig. 8c) proving that the IO-MMMs are cell-associated, interact with the plasma membrane, and are subsequently internalized in clusters. To validate the intracellular location, TEM imaging was also employed. After only 2 hrs of IO-MMM cell incubation, particles were seen interacting with plasma membrane, microvilli, and within cells (Fig. 9a,b). Representative TEM micrographs clearly show that the IO-MMMs are attached and then internalized, individually or in clusters, by the cells via the plasma membrane. Despite their relatively larger sizes, the particles were majorly seen internalized in the cytosol, but not in the nucleus, in agreement with previous reports67. The particles’ engulfment took place without the particles being surface functionalized by polymeric or targeting groups, consistent with earlier reported works where particles up to 1000 nm were found to be abundantly present in different areas of the cytoplasm86,87. Commonly, cells uptake particles through one form of endocytic mechanisms, engulfed within the cell membrane, and contained intracellularly in membrane-bound vesicles which then traffic via endolysosomal pathways88. Studies have revealed that the particles’internalization, and their subsequent intracellular routing, is strongly dependent on their size, shape, composition, and surface properties, as well as on cell-specific parameters such as cell type, protein expression levels, or cell cycle phase89,90. The size-dependent interaction of different particles with the cell membrane is likely related to the membrane-wrapping process that initiates endocytosis, as has been observed here. Despite huge efforts in this area, it remains challenging and ambiguous to reliably correlate a particular cellular response with particle size. However, it is generally accepted that larger particles (>500 nm) are predominantly taken up via nonspecific energy-dependent membrane-tangled internalization and macropinocytosis91. Moreover, the observed uptake may be possibly due to the high adsorption of phospholipid head groups on the plasma membranes to surface hydroxyl groups (Fe-OH) via a proven Fe–O–H–O–P mechanism92. We, thus, anticipate the internalization to occur by a combination of mechanisms, most notably non-selective macropinocytosis93, where internalization of upper-size-limit particles up to 3-μm was elegantly demonstrated90. After being uptaken, the particles subsequently traffic to lysosomes to be hydrolyzed and broken down. Interestingly, in some micrographs it was possible to observe agglomerates of iron oxide clusters closer to the nucleus, suggesting their traffic to acidic lysosomal compartments (Supplemental Fig. S7). It is worth noting that no major alternations in cellular structures or micro-organelles was apparent, confirming the biocompatibility of the utilized IO-MMM carriers. As compared to particles with smaller sizes (<200 nm), although the net internalization might be less, the actual drug release into the cytosol may well be higher, due to the prolonged residence time of the microparticles inside, thus avoiding rapid lysosomal degradation91. Another important benefit, is that microparticles cannot passively diffuse into cells, enter organelles (i.e. mitochondria), and disrupt normal cell functions, which thus minimizes potential toxic and systemic effects of smaller nanoparticles after administration94. According to our knowledge, this is the first report systematically studying the intracellular uptake of iron oxide mesostructures of sizes (>500 nm).

Collectively, all the results imply that the major route of drug delivery is through differential uptake of drug@IO-MMMs into the cells, followed by sustained release of drugs intracellularly in a pH-dependent manner, causing apoptotic cell death. It is, thus, repeatedly evident that while free drugsare internalized by passive diffusion, the uptake of iron oxide nano/microparticles are rather directed by endocytic trafficking mechanisms. Regardless of the exact and complex intracellular routing, our results strongly suggest that using the IO-MMM carriers described here is superiorly advantageous, as it reduces the unwanted diffusive side effects of the free drugs allowing selective synergistic anticancer drug delivery.

### Penetration of drug@IO-MMMs into tumor tissue

In order to investigate the penetration of Daun/Tam@IO-MMM formulation into tumor tissues, we treated primary breast tumor surgery sections derived directly from primary lesions with either Daun/Tam@IO-MMMs or free Daun/Tam at equivalent drug concentrations. Due to inadequate drug accumulation, tumor drug resistance, and limited drug penetration of chemotherapeutic drugs to tumor tissues95, it is imperative to design advanced delivery systems to enhance tumor accumulation, improve drug delivery, and, hence, enhance overall efficacies96. While free drugs diffuse nonspecifically with typically limited penetration to interior of tumors, drug delivery carriers have premises to better accumulate in the tumor tissues via the acknowledged enhanced permeability and retention (EPR) effect and kill the cancer cells residing in the center, resulting in enhanced therapies4,11,97. If anticancer drugs are unable to access and penetrate the cells within a tumor, then their therapeutic effectiveness will be hampered, no matter what is their actual potency98. Despite the existence of different strategies for stimuli-responsive triggered drug release systems (i.e. pH, redox, enzymes, heat, light etc) intended to better penetrate tumors, many barriers still exist16,99. In fact, the tumor penetration is a passive process that requires a bio-stable particles of appropriate sizes (not too small nor too big) loaded with high capacities of drugs to allow extravasation of the particles across the hyper-permeable tumor vessels and effective diffusion through the tumor interstitial space100. Primary tumor vessels have a defective cellular lining composed of disorganized, loosely connected, overlapping or sprouting endothelial cells where the gaps have been reported to range between 300 nm and 4700 nm101,102. This particularly contributes to tumor vessel leakiness and permits access of therapeutic vehicles. The challenge remains to deliver the particles throughout the tumor and its metastases given the heterogeneity of tumor microenvironment along with the limitations of spatial and temporal changes in the expression of the target. One of the most promising directions is, thus, to employ an internal pH-dependent sustainable delivery system that accumulates in the tumor and delivers drug-loaded particles into the target cells, releasing their loads intratumorally. Although nano-sized materials have been advocated for drug delivery to tumors, micron-sized particles such as Dox-loaded APMS have also shown promise in enhancing intracellular uptake of Dox and inhibiting tumor growth without any systemic toxicity both in vitro and in vivo103. Therefore and based on the promising in vitro cellular studies obtained, we anticipate that the pH-triggered IO-MMM formulation designed here, will attain the above-mentioned criteria.

Dissected breast cancer tumor tissues were cut to ~1 mm3 of equivalent sizes and were cultured to mimic oxygen, nutrient, and energy gradients similar to those found in vivo. The treatment was performed for 2 weeks at 37 °C and 5% CO2. Z-stack confocal microscopy images starting from top to bottom of patient biopsy tissue sample exposed to Daun/Tam@IO-MMMs were acquired (Fig. 10a). As shown, extensive distribution of red Daun fluorescence through the tumor from top to bottom was observed (a middle selected slice of the z-stack images is displayed in Fig. 10b). 3D reconstructed images excitingly showed areas of extensive red fluoresence deep inside the tissue(~105 μm depth), signaling significant intracellular Daun release inside the tumor (Fig. 10c). It is anticipated that the particles penetrated inside the leaky vasculature of tumor tissue to certain level, releasing the drugs internally. In comparison, the amount of red fluorescence penetration was noticeably much lower for the free drug (Supplemental Fig. S8). Thus, form our results, it is clear that the Daun/Tam@IO-MMM formulation penetrated deeper and delivered enhanced anticancer drugs into the tumor compared to the free diffusive drugs. Furthermore, optical photographs of tissue sections before and after treatment were also captured to register the shrinkage of tissue mass due to the different treatments (Fig. 10d). Even with the naked eye, the shrinkage of Daun/Tam@IO-MMMs-treated tumor tissue compared to free drug-treated tissue was obvious, confirming the potential of IO-MMMs as effective drug delivery vehicle penetrating inside the tumor via the EPR effect, and significantly improving the recognized limited tumor penetration of free drugs. It is to be noted that similar tumor tissues were also treated with either Daun@IO-MMMs or Dox@IO-MMMs alone, however, lower therapeutic effects were observed, signifying that the co-delivery of Daun and Tam together synergistically exert their anticancer functions to achieve a better outcome.This designed multi-drug IO-MMM formulation is, thus, promising to enhance the effectiveness of the therapeutic drugswith optimal doses, opening new opportunities for in vivo combined therapeutics. This combinatory drug therapy depicts the synergistic enhanced antitumor effectswhere lower doses ofeach therapeutic drugs can be used, which in turn, will have a dramaticeffect in cancer treatments, minimizing the typical toxicity towards the healthy cells. Furthermore, magnetic guidance on this system is potentially feasible by focusing an external magnetic field on the target after injection of IO-MMMs.

## Conclusion

In summary, unique bio-stable iron oxide mesoconstructs with remarkably high surface areas and pore volumes were prepared by hard-templated methodology using APMS as the silica template. The as-prepared IO-MMM mesostructures can be loaded with hydrophilic and hydrophobic therapeutic anticancer drugs, or a combination of both drugs, on demand. The combinatory drug@IO-MMM formulation demonstrated cellular uptake and pH-dependent drug release with enhanced cytotoxic effects towards different types of cancerous cells. Particularly, Daun/Tam@IO-MMMs were found to be highly potent to the different metastatic breast and colorectal cancer cells, with considerably less toxicity towards the normal primary cells, suggesting huge potentials as selective anti-cancer agents for cancer therapeutics. Importantly, this drug-loaded IO-MMM formulation was also able to effectively accumulate in patient primary tumor tissues, delivering the cytotoxic drugs and killing the tumor cells inside. The Daun/Tam@IO-MMM vehicle described here facilitates packing of chemo/hormonal therapeutic anticancer drugs without premature release at physiological pH, recognizes the target cells, and finally releases the drugs at the intracellular site of tumor cells to induce apoptosis and shrinkage. Notably, this combinatory mesoporous drug@IO-MMM platform display not only a pH-dependent but potentially a magneto-responsive drug release behavior, opening new premises for in vivo imaging, cancer monitoring, and theranostics.

## Materials and Methods

Unless otherwise indicated, all chemicals and solvents were obtained from commercial suppliers and used as received without further purification. Iron (III) chloride hexahydrate (FeCl3·6H2O), zinc metal powder, magnesium powder, cetyltrimethylammonium bromide (CTAB), tetraethyl orthosilicate (TEOS),3-aminopropyltriethoxysilane (APTES), sodium fluoride (NaF), concentrated HCl, ammonium hydroxide (NH4OH), iron (II) chloride tetrahydrate (FeCl2.4H2O), polyacrylic acid (PAA), fluorescein isothiocyanate(FITC) as well as the drugs Doxorubicin (Dox), Daunorubicin (Daun), and Tamoxifen (Tam) were all purchased from UFC Biotechnology. Dulbecco’s Phosphate Buffered Saline (DPBS), Phosphate Buffered Saline (PBS), Advanced Dulbecco’s Modified Eagle Medium (DMEM), Phenol-red free DMEM, Fetal Bovine Serum (FBS), Hoechst 33342 stain, L-Glutamine, and Penicillin-Streptomycin (Pen-Strep) were all purchased from Invitrogen. MTT (Thiazolyl Blue Tetrazolium Bromide) powder was purchased from Bioworld, USA. All cell lines were purchased from the American Type Culture Collection (ATCC) and grown in Advanced DMEM supplemented with 10% FBS and 1% Penicillin/Streptomycin. Human cancerous cells used in this study are: MCF7 (Michigan Cancer Foundation-7 metastatic breast cancer cell line isolated from a 69-year-old Caucasian woman); HCT-8 (Human ileocecal colorectal adenocarcinoma cell line isolated from a 67-year-old male); KAIMRC1 (naturally immortalized KAIMRC1 breast cancer cells isolated from a 62-year-old Arab female suffering from stage IIB breast cancer); along with primary normal fibroblast-like cells (isolated from a breast cancer patient after surgical procedure) used as a control. Cells were cultured for at least 24 hrs before conducting the experiments. All experiments were conducted in triplicates and mean averages were plotted. Tumor surgical sections were collected after examination by a certified pathologist, prepared for analysis on the same day, and cultured in advanced DMEM. Tissues were collected at the time of surgery after written informed consent was obtained from patients at King Abdulaziz Medical City, National Guard Hospital, under approval from KAIMRC Institutional Review Board (IRB). The tissue biopsies were surgical remnants which were consequently used in this study. All methods were performed in accordance with standard guidelines and regulations, and the procedures of tissue experiments were approved by Bioethics Department, IRB, KAIMRC (RC16/096).

### Characterization

SEM images were processed usinga FEI NanoSEM 450 scanning electron microscope at 15 kV. EDX were acquired using same system which is supplied with EDAX® AMETEK® (material analysis division). TEM images were collected on a JEOL-JEM 1400 operating at 120 kV using Gatan camera with Digital Micrograph Imaging software. Samples were prepared by depositing 1 μl of the nanoparticles dispersed onto 400 mesh Formvar/Carbon-supported copper grid. X-ray diffraction (XRD) patterns were recorded using Bruker D8 Diffractometer using Cu Kα radiation operated at 40 kV and 2 Ɵ scan range from 20° to 70°. FTIR spectra (400–4000 cm−1) were recorded as KBr pellets using Shimadzu IRAffinity-1. DLS and zeta potential measurements were assessed on Malvern Zetasizer Nano ZS instrument. Calcinations were carried out either under flowing air or under argon. The following heating profile was used for APMS calcination: 2 °C/min ramp to 450 °C, 240 min hold at 450 °C, 10 °C/min ramp to 550 °C, 480 min hold at 550 °C. Confocal images were visualized using inverted Zeiss LSM 780 multiphoton laser scanning confocal microscope equipped with 20× and 40× (oil immersion) objectives and Axiocam cameras. Z-stack images of tissue sections were acquired using above mentioned Zeiss LSM780 microscope.

#### Preparation of APMS

APMS was synthesized following our previous work where TEOS was used as the silica source and CTAB as the structure directing agent. Briefly, CTAB (0.7 g), H2O (15 mL), ethanol (5 mL), and concentrated HCl (1.7 mL) were vigorously stirred until the surfactant was dissolved. TEOS (1.4 mL) was then slowly added while stirring. After 5 min, NaF (0.5 M in water, 1.85 mL) was added and stirring was continued until the mixture turned turbid. The mixture was then quickly transferred to a Teflon bottle and heated at 100 °C for 60 mins. The resulting APMS precipitate was cooled to room temperature, collected by vacuum filtration, repeatedly washed with water and ethanol, and dried under vacuum. Calcination at 550 °C under air to remove the CTAB surfactant afforded calcined APMS ready for iron impregnation.

#### Preparation of IO-MMMs

IO-MMMs were prepared following modified literature procedures39,62 using calcined APMS as the hard template. 0.175 g of APMS was dispersed in 10 mL of 0.5 M aqueous solution of FeCl3.6H2O. Trace amounts of zinc (or magnesium)was then added and the reaction mixture was aged for 24 hrs under constant stirring at room temperature. The resulting material was carefully decanted to separate the zinc, purified by successive centrifugation and repeated washing with water and ethanol, and finally dried under vacuum. This impregnation process was then repeated with 0.5 M of FeCl3 aqueous solution to ensure complete iron impregnation. The obtained product was then heated to 350 °C at 2 °C/min for 3 h under argon atmosphere and left at this temperature for 4 h. Thermal treatment at 350 °C under inert atmosphere is adequate to completely decompose and convert iron species to γ-Fe2O3 nanocrystals, without formation of other phases. Finally, the sample was treated several times with 5 M hot NaOH solution to completely remove the APMS silica template, purified by centrifugation, washed with water and ethanol, and then dried in an oven at 100 °C. IO-MMMs were dispersed in water for cellular studies. It is worth pinpointing that different FeCl3 aqueous solutions (0.25, 0.5, 0.75, and 1 M) for impregnation were tested. No much difference was observed when greater than 0.5 M solutions were used. This experimental procedure can be extended to a wider range of binary transition metal oxides by simply using a wide range of the commercially available cheap metal salt precursors.

#### Preparation of IO-MMNs

First, PAA-MNPs were prepared according to our previous report72. In a generalized procedure, 5 mL aqueous solution of FeCl3.6H2O (0.10 g) and PAA (0.10 g) were mixed and magnetically stirred under argon in a degassed vial for 15 min. Aqueous solution of FeCl2.4H2O (0.05 g) was then injected. After stirring for a few minutes, 1 mL of ammonium hydroxide (30%) was slowly added and the mixture was heated to 80 °C and vigorously stirred for 90 min. The black precipitate of PAA-MNPs formed was cooled to room temperature by removing the heat source, isolated via centrifugation (4500 rpm, 10 min), washed repeatedly with water, isopropanol, and ethanol, and finally redispersed in water. Centrifugation (4500 rpm, 20 min) was then applied to remove any undispersed residue. The stable colloidal PAA-MNPs solution was stored at ambient conditions for several months. No precipitation over the course of months was observed. It is to be noted that when hexylamine (0.5 mL) was added in the synthesis, PAA-MNPs clumpand precipitate, and the particles were found to be dispersible in ethanol. 0.10 g of as-prepared calcined APMS was then impregnated/wetted with aqueous or ethanolic solution of PAA-MNPs (0.1 to 2 mg/mL) and the reaction mixture was stirred for 24 hrs at room temperature. The resulting material was then centrifuged, washed repeatedly with water and ethanol, dried under vacuum, and thermally treated as before. Etching using5 M NaOH solution afforded very low yields of IO-MMNs instead, with low BET surface areas and pore volumes (Supplemental Fig. S2). Even when repeated impregnation was performed, no much of a change in the final product was observed.

#### Magnetic Manipulation of IO-MMM Magnetized Cells

Prior to the experiment, cells were seeded on 35 mm Ibidi dishes for 24 h at 37 C and 5% CO2. Cells were then treated with IO-MMMs for 1 hr, washed with PBS, stained with HOECHST 33342 nuclear stain, and imaged using EVOS FL Auto Imaging System in the presence or absence of a permanent magnet. Both transmitted light and blue fluorescence images were acquired. Optical camera photos were also shot recording the aggregation of cells in the presence of the magnet.

$${\rm{Loading}}\,{\rm{Efficiency}}=({{\rm{W}}}_{{\rm{l}}}/{{\rm{W}}}_{0})\times 100$$

where Wl is the amount of drug loaded onto the particles and W0 is the amount of drug in the initial solution. The amount of drug loaded onto IO-MMMs was calculated from the difference between the initial drug concentration and the drug concentration left in the supernatant.

#### Drug Release

In a typical study, 5 mg of drug@IO-MMMs were suspended in 1 mL PBS buffer at two different pH values (pH = 7.4 and pH = 4.5) and gently rotated at 37 °C in an oven provided with a precise control in the temperature within 0.01 °C. The concentration of drugs in the supernatant was determined at fixed time intervals by UV-vis spectroscopy. At specific time points, supernatant aliquots obtained by centrifugation were taken from each tube, measured and returned to their respective tubes after UV-vis measurements. The drug concentration could be directly calculated from the measured absorbance. Triplicate aliquots were run for each time interval, and average values plotted. The percent drug release was calculated using the equation below:

$$\% \,{\rm{Drug}}\,{\rm{Release}}=({{\rm{Abs}}}_{({\rm{t}})}\,{\rm{of}}\,{\rm{released}}\,{\rm{drug}}/{{\rm{Abs}}}_{({\rm{t}}0)})\times 100$$

#### Cell Viability Assays

All cell lines were seeded in a 96-well plate at a density of 5 × 104 cells/well and incubated at 95%/5% humidified air/CO2 and 37 °C. Post 24 hrs, the media was removed and fresh phenol-red free DMEM containing 0.5% FBS was added to the cells. Cells were then treated with various concentrations of IO-MMMs, drugs@IO-MMMs, and respective free drugs in 200 μL supplemented DMEM. The wells at all edges were left free of cells in order to prevent edge effect. An additional row with only the particles was added in order to account for the particle effect. After 48 hrs of incubation, the media was removed and the cells were washed with PBS. Cell viability was then determined using the MTT viability assay following the manufacturer’s protocol. Briefly, 20 µl of MTT reagent (5 mg/mL) was added to each well and kept for 4 hrs at 37 °C in the incubator. The supernatant was then removed, and the MTT formazan were dissolved in 100 µl dimethyl sulfoxide (DMSO). The absorbance was measured on Molecular Devices SpectraMax microplate absorbance reader at 570 nm. The percentage of viable cells was calculated as the ratio of the absorbance of the treated group, divided by the absorbance of the control group, multiplied by 100. The absorbance from the untreated control cells was set as 100% viable.

#### Live Confocal Microscopy Imaging

Cells were incubated in 8-well dish ((iBidi, Germany) for 24 hrs prior to particle exposure. After removing the supernatant, cells were then exposed to IO-MMMs (10 μg/mL), Daun/Tam@IO-MMMs (10 μg/mL NPs; 2.50 μg/mL Daun; 1.75 μg/mL Tam), or equivalent concentration of free Daun/Tam. The cells were incubated for different periods of time (i.e. 6 and 24 hrs). Hoechst 33342 stain was then added. The cells were allowed to settle down for 20 min before microscopic visualization. To mimic physiological conditions, no fixation of cells was conducted.

#### Fluorescence Activated Cell Sorting (FACS)

Cancerous and normal cells (1 × 105 cells per well) were seeded in 12 well culture dishes, incubated for 24 h, and then treated for different periods of time with FITC-labeled IO-MMMs (10 µg/mL) prepared following literature procedure104. Both live and dead cells were collected, pelleted, washed with PBS, and then transferred to FACS tubes for analysis. Flow cytometry measurements were then assessed. Triplicate experiments were conducted. Mean values were plotted and error bars represents standard deviations.

#### Scanning Electron Microscopy of Cell Specimens

Cells were treated with IO-MMMs (10 µg/mL) for 6 hrs prior to fixation. The specimens were then processed for SEM by the following method: Cells were first fixed with 4% paraformaldehyde at 4 °C for 30 min and then dehydrated with graded concentrations of ethanol. The cells were then transferred to appropriate carbon taped stubs (Ted Pella, USA) for imaging. To enhance the electron conductivity, samples were coated with gold/palladium (Au/Pd) by sputter coating and examined on a FEI NanoSEM 450 scanning electron microscope at 15 kV.

#### Transmission Electron Microscopy of Cell Specimens

Cells were first treated with the IO-MMMs for 2 hrs as described above. The specimens were then processed for TEM by the following method: the specimen was fixed in 4% glutaraldehyde in 0.1 M PBS (pH 7.4) for 1 hr. After washing in the same buffer, the sample was post-fixed in 1% OsO4 in 0.1 M PBS (pH 7.4) for 1 hr, followed by PBS washing. The specimen was then dehydrated in a series of acetone solutions and infiltrated in acetone: resin (1:1) for 1 hr, and then with acetone: resin (1:2) for more than 3 hrs. The specimen was then embedded in epoxy resin (Araldite) and placed in an oven at 80 °C overnight to polymerize. Ultrathin sections were obtained with Ultramicrotome (RMS), mounted on copper grids, and stained for contrast with heavy metal stains (uranyl acetate and lead citrate). TEM images were then collected on a JEOL-JEM 1200 operating at 120 kV using Gatan camera with Digital Micrograph Imaging software.

#### Surgical tissue processing

Human breastcancer patient tissue resections were placed in a sterile conical tube containing PBS on wet ice during transportation from the operating room to the research laboratory. Resections were transported to the laboratory within 30 min of clinical sample collection. Upon arrival, the tissue resections were examined by a certified pathologist. Resections were then manually minced using a sterile scalpel and washed thoroughly with PBS. Then small tumor pieces were transferred into 8-well µ-dishes (Ibidi, Germany) containing advanced DMEM supplemented with 10% FBS, 1% L-glutamine, and 1% antibiotics (Pen-Strep). Tumor tissue sections were treated with the different drug@IO-MMMs or equivalent concentration of free drugs for 7 days prior to imaging with an inverted Zeiss LSM 780 multiphoton laser scanning confocal microscope equipped with 20× and 40× (oil immersion) objectives and Axiocam cameras.

## Data Availability

The data that supports the findings reported herein are available upon request from the corresponding author.

## References

1. 1.

Arruebo, M. et al. Assessment of the evolution of cancer treatment therapies. Cancers 3, 3279–3330 (2011).

2. 2.

Venditto, V. J. & Szoka, F. C. Jr. Cancer Nanomedicines: So Many Papers and So Few Drugs! Adv. Drug. Del. Rev. 65, 80–88 (2013).

3. 3.

Sengupta, S. Cancer Nanomedicine: Lessons for Immuno-Oncology. Trends in Cancer 3, 551–560 (2017).

4. 4.

Schroeder, A. et al. Treating metastatic cancer with nanotechnology. Nat Rev. Cancer 12, 39–50 (2012).

5. 5.

Jain, R. K. & Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7, 653–664 (2010).

6. 6.

Guo, L. et al. Combinatorial Photothermal and Immuno Cancer Therapy Using Chitosan-Coated Hollow Copper Sulfide Nanoparticles. ACS Nano 8, 5670–5681 (2014).

7. 7.

Tang, X.-L. et al. pH-Responsive Magnetic Mesoporous Silica-Based Nanoplatform for Synergistic Photodynamic Therapy/Chemotherapy. ACS Appl. Mater. Interfaces 10, 15001–15011 (2018).

8. 8.

Liu, Y. et al. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy. Acta Biomater. 66, 310–324 (2018).

9. 9.

Rosenholm, J. M., Sahlgren, C. & Linden, M. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles - opportunities & challenges. Nanoscale 2, 1870–1883 (2010).

10. 10.

Tiwari, G. et al. Drug delivery systems: An updated review. Int. J. Pharm. Investig. 2, 2–11 (2012).

11. 11.

El-Boubbou, K. Magnetic iron oxide nanoparticles as drug carriers: clinical relevance. Nanomedicine 13, 953–971 (2018).

12. 12.

Soler-Illia et al. Chemical Strategies To Design Textured Materials:  from Microporous and Mesoporous Oxides to Nanonetworks and Hierarchical Structures. Chem. Rev. 102, 4093–4138 (2002).

13. 13.

Lee, J. E., Lee, N., Kim, T., Kim, J. & Hyeon, T. Multifunctional Mesoporous Silica Nanocomposite Nanoparticles for Theranostic Applications. Acc. Chem. Res. 44, 893–902 (2011).

14. 14.

Niedermayer, S. et al. Multifunctional polymer-capped mesoporous silica nanoparticles for pH-responsive targeted drug delivery. Nanoscale 7, 7953–7964 (2015).

15. 15.

Zhao, Z. et al. Magnetite nanoparticles as smart carriers to manipulate the cytotoxicity of anticancer drugs: magnetic control and pH-responsive release. J. Mater. Chem. 22, 15717–15725 (2012).

16. 16.

Mura, S., Nicolas, J. & Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 12, 991–1003 (2013).

17. 17.

Knežević, N. Ž., Ruiz-Hernández, E., Hennink, W. E. & Vallet-Regí, M. Magnetic mesoporous silica-based core/shell nanoparticles for biomedical applications. RSC Adv. 3, 9584–9593 (2013).

18. 18.

Kim, J. et al. Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. Angew. Chem., Int. Ed. 47, 8438–8441 (2008).

19. 19.

Lu, F., Popa, A., Zhou, S., Zhu, J.-J. & Samia, A. C. S. Iron oxide-loaded hollow mesoporous silica nanocapsules for controlled drug release and hyperthermia. Chem. Commun. 49, 11436–11438 (2013).

20. 20.

Gan, Q. et al. Endosomal pH-activatable magnetic nanoparticle-capped mesoporous silica for intracellular controlled release. J. Mater. Chem. 22, 15960–15968 (2012).

21. 21.

Chen, D. Y. et al. Modification of magnetic silica/iron oxide nanocomposites with fluorescent polymethacrylic acid for cancer targeting and drug delivery. J. Mater. Chem. 20, 6422–6429 (2010).

22. 22.

Qiu, X.-L. et al. Sugar and pH dual-responsive snap-top nanocarriers based on mesoporous silica-coated Fe3O4 magnetic nanoparticles for cargo delivery. Chem. Commun. 51, 4237–4240 (2015).

23. 23.

Xuan, S. H. et al. Synthesis of Biocompatible, Mesoporous Fe3O4 Nano/Microspheres with Large Surface Area for Magnetic Resonance Imaging and Therapeutic Applications. ACS Appl. Mater. Interfaces 3, 237–244 (2011).

24. 24.

Li, D. et al. Doxorubicin-Conjugated Mesoporous Magnetic Colloidal Nanocrystal Clusters Stabilized by Polysaccharide as a Smart Anticancer Drug Vehicle. Small 8, 2690–2697 (2012).

25. 25.

Benyettou, F. et al. Mesoporous γ-Iron Oxide Nanoparticles for Magnetically Triggered Release of Doxorubicin and Hyperthermia Treatment. Chem. Eur. J. 22, 17020–17028 (2016).

26. 26.

Firouzi, A. et al. Cooperative organization of inorganic-surfactant and biomimetic assemblies. Science 267, 1138–1143 (1995).

27. 27.

Soler-Illia, G., Crepaldi, E. L., Grosso, D. & Sanchez, C. Block copolymer-templated mesoporous oxides. Curr. Opin. Colloid Interface Sci. 8, 109–126 (2003).

28. 28.

Yang, P. D., Zhao, D. Y., Margolese, D. I., Chmelka, B. F. & Stucky, G. D. Generalized syntheses of large-pore mesoporous metal oxides with semicrystalline frameworks. Nature 396, 152–155 (1998).

29. 29.

Gu, D. & Schüth, F. Synthesis of non-siliceous mesoporous oxides. Chem. Soc. Rev. 43, 313–344 (2014).

30. 30.

Guo, S. J., Li, D., Zhang, L. M., Li, J. & Wang, E. K. Monodisperse mesoporous superparamagnetic single-crystal magnetite nanoparticles for drug delivery. Biomaterials 30, 1881–1889 (2009).

31. 31.

Su, Y.-L. et al. Targeted Mesoporous Iron Oxide Nanoparticles-Encapsulated Perfluorohexane and a Hydrophobic Drug for Deep Tumor Penetration and Therapy. Theranostics 5, 1233–1248 (2015).

32. 32.

Liu, X., Hu, Q., Fang, Z., Wu, Q. & Xie, Q. Carboxyl Enriched Monodisperse Porous Fe3O4 Nanoparticles with Extraordinary Sustained-Release Property. Langmuir 25, 7244–7248 (2009).

33. 33.

Sanchez, C. et al. Designed hybrid organic-inorganic nanocomposites from functional nanobuilding blocks. Chem. Mater. 13, 3061–3083 (2001).

34. 34.

Sun, B. et al. Synthesis of Mesoporous α-Fe2O3 Nanostructures for Highly Sensitive Gas Sensors and High Capacity Anode Materials in Lithium Ion Batteries. J. Phys. Chem. C 114, 18753–18761 (2010).

35. 35.

Yang, P. D., Zhao, D. Y., Margolese, D. I., Chmelka, B. F. & Stucky, G. D. Block copolymer templating syntheses of mesoporous metal oxides with large ordering lengths and semicrystalline framework. Chem. Mater. 11, 2813–2826 (1999).

36. 36.

Mitra, A., Vázquez-Vázquez, C., López-Quintela, M. A., Paul, B. K. & Bhaumik, A. Soft-templating approach for the synthesis of high surface area and superparamagnetic mesoporous iron oxide materials. Micropor. Mesopor. Mat. 131, 373–377 (2010).

37. 37.

Delahaye, E. et al. “Nanocasting”: Using SBA-15 silicas as hard templates to obtain ultrasmall monodispersed gamma-Fe2O3 nanoparticles. J. Phys. Chem. B 110, 26001–26011 (2006).

38. 38.

Dong, A. G. et al. General synthesis of mesoporous spheres of metal oxides and phosphates. J. Am. Chem. Soc. 125, 4976–4977 (2003).

39. 39.

Lu, A. H. et al. Spatially and Size Selective Synthesis of Fe-Based Nanoparticles on Ordered Mesoporous Supports as Highly Active and Stable Catalysts for Ammonia Decomposition. J. Am. Chem. Soc. 132, 14152–14162 (2010).

40. 40.

Deng, X., Chen, K. & Tüysüz, H. Protocol for the Nanocasting Method: Preparation of Ordered Mesoporous Metal Oxides. Chem. Mater. 29, 40–52 (2017).

41. 41.

Jiao, F. et al. Ordered mesoporous Fe2O3 with crystalline walls. J. Am. Chem. Soc. 128, 5468–5474 (2006).

42. 42.

Kleitz, F., Choi, S. H. & Ryoo, R. Cubic Ia3d large mesoporous silica: synthesis and replication to platinum nanowires, carbon nanorods and carbon nanotubes. Chem. Commun., 2136–2137 (2003).

43. 43.

Shin, H. J., Ryoo, R., Liu, Z. & Terasaki, O. Template Synthesis of Asymmetrically Mesostructured Platinum Networks. J. Am. Chem. Soc. 123, 1246–1247 (2001).

44. 44.

Laha, S. C. & Ryoo, R. Synthesis of thermally stable mesoporous cerium oxide with nanocrystalline frameworks using mesoporous silica templates. Chem. Commun., 2138–2139 (2003).

45. 45.

Dickinson, C. et al. Formation Mechanism of Porous Single-Crystal Cr2O3 and Co3O4 Templated by Mesoporous Silica. Chem. Mater. 18, 3088–3095 (2006).

46. 46.

Kim, S. S. et al. Preparation of Highly Ordered Mesoporous TiO2 Materials with Crystalline Framework from Different Mesostructured Silica Templates via Nanoreplication. Chem. Lett. 37, 140–141 (2007).

47. 47.

Sun, X. et al. Container Effect in Nanocasting Synthesis of Mesoporous Metal Oxides. J. Am. Chem. Soc. 133, 14542–14545 (2011).

48. 48.

Jiao, F. et al. Synthesis of ordered mesoporous Fe3O4 and γ-Fe2O3 with crystalline walls using post-template reduction/oxidation. J. Am. Chem. Soc. 128, 12905–12909 (2006).

49. 49.

Crowley, T. A. et al. Synthesis of metal and metal oxide nanowire and nanotube arrays within a mesoporous silica template. Chem. Mat. 15, 3518–3522 (2003).

50. 50.

Yang, H. F. et al. One-step synthesis of highly ordered mesoporous silica monoliths with metal oxide nanocrystals in their channels. Adv. Func. Mater. 15, 1377–1384 (2005).

51. 51.

Shon, J. K. et al. Synthesis of Mesoporous Iron Oxide Nanoparticles from Mesoporous Silica Template Via Nano-Replication. Func.Mater. Lett. 1, 151–154 (2008).

52. 52.

Shon, J.K. et al. Facile synthesis of highly ordered mesoporous silver using cubic mesoporous silica template with controlled surface hydrophobicity. Chem. Commun., 650–652 (2009).

53. 53.

Fröba, M., Köhn, R., Bouffaud, G., Richard, O. & van Tendeloo, G. Fe2O3 Nanoparticles within Mesoporous MCM-48 Silica:  In Situ Formation and Characterization. Chem. Mater. 11, 2858–2865 (1999).

54. 54.

Samanta, S. et al. Synthesis and Characterization of Iron-Rich Highly Ordered Mesoporous Fe-MCM-41. Ind. Eng. Chem. Res. 42, 3012–3018 (2003).

55. 55.

Suteewong, T. et al. Ordered mesoporous silica nanoparticles with and without embedded iron oxide nanoparticles: structure evolution during synthesis. J. Mater. Chem. 20, 7807–7814 (2010).

56. 56.

Tsoncheva, T. et al. Critical evaluation of the state of iron oxide nanoparticles on different mesoporous silicas prepared by an impregnation method. Micropor. Mesopor. Mat. 112, 327–337 (2008).

57. 57.

Yang, H. et al. One-Step Nanocasting Synthesis of Highly Ordered Single Crystalline Indium Oxide Nanowire Arrays from Mesostructured Frameworks. J. Am. Chem. Soc. 125, 4724–4725 (2003).

58. 58.

El-Boubbou, K., Schofield, D. A. & Landry, C. C. Enhanced Enzymatic Activity of OPH in Ammonium-Functionalized Mesoporous Silica: Surface Modification and Pore Effects. J. Phys. Chem. C 116, 17501–17506 (2012).

59. 59.

El-Boubbou, K., Schofield, D. A. & Landry, C. C. Enhanced Enzymatic Thermal Stability and Activity in Functionalized Mesoporous Silica Monitored by 31P NMR. Adv. Healthc. Mater. 1, 183–188 (2012).

60. 60.

Tüysüz, H., Salabaş, E. L., Weidenthaler, C. & Schüth, F. Synthesis and Magnetic Investigation of Ordered Mesoporous Two-Line Ferrihydrite. J. Am. Chem. Soc. 130, 280–287 (2008).

61. 61.

Kong, A., Wang, H., Li, J. & Shan, Y. Preparation of super paramagnetic crystalline mesoporous γ-Fe2O3 with high surface. Mater. Lett. 62, 943–945 (2008).

62. 62.

Shen, W., Qi, Z. & Naito, S. Unique preparation method for mesoporous γ-Fe2O3 simplified by using surfactant contained mesoporous silica as a hard template. Mater. Res. Innov. 19, 51–53 (2015).

63. 63.

Yuan, S. M., Zhou, Z. & Li, G. Structural evolution from mesoporous α-Fe2O3 to Fe3O4@C and γ-Fe2O3 nanospheres and their lithium storage performances. Crystengcomm 13, 4709–4713 (2011).

64. 64.

El-Boubbou, K. et al. Ultra-Small Fatty Acid-Stabilized Magnetite Nanocolloids Synthesized by In Situ Hydrolytic Precipitation. Journal of Nanomaterials, Article ID 620672, 620611 pages (2015).

65. 65.

El-Boubbou, K. Acid-Stabilized Iron-based Metal Oxide Colloidal Nanoparticles, and Methods Thereof. US Patent 20170110228 A1 (2017).

66. 66.

O’Regan, R. M. & Jordan, V. C. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol. 3, 207–214 (2002).

67. 67.

Llinàs, M. C. et al. Preparation of a mesoporous silica-based nano-vehicle for dual DOX/CPT pH-triggered delivery. Drug delivery 25, 1137–1146 (2018).

68. 68.

Fang, J. et al. Quercetin and doxorubicin co-delivery using mesoporous silica nanoparticles enhance the efficacy of gastric carcinoma chemotherapy. Int. J. Nanomedicine 13, 5113–5126 (2018).

69. 69.

Hu, F. X., Neoh, K. G. & Kang, E. T. Synthesis and in vitro anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA composite nanoparticles. Biomaterials 27, 5725–5733 (2006).

70. 70.

Heidari Majd, M. et al. Tamoxifen loaded folic acid armed PEGylated magnetic nanoparticles for targeted imaging and therapy of cancer. Coll. Surf. B Biointerfaces 106, 117–125 (2013).

71. 71.

Vivek, R. et al. HER2 Targeted Breast Cancer Therapy with Switchable “Off/On” Multifunctional “Smart” Magnetic Polymer Core–Shell Nanocomposites. ACS Appl. Mater. Interfaces 8, 2262–2279 (2016).

72. 72.

El-Boubbou, K. et al. Magnetic Fluorescent Nanoformulation for Intracellular Drug Delivery to Human Breast Cancer, Primary Tumors, and Tumor Biopsies: Beyond Targeting Expectations. Bioconjugate Chem. 27, 1471–1483 (2016).

73. 73.

El-Boubbou, K., Azar, D., Bekdash, A. & Abi-Habib, R. J. Doxironide Magnetic Nanoparticles for Selective Drug Delivery to Human Acute Myeloid Leukemia. J. Biomed. Nanotechnol. 13, 500–512 (2017).

74. 74.

Zhang, G. et al. Hydroxylated Mesoporous Nanosilica Coated by Polyethylenimine Coupled with Gadolinium and Folic Acid: A Tumor-Targeted T1 Magnetic Resonance Contrast Agent and Drug Delivery System. ACS Appl. Mater. Interfaces 7, 14192–14200 (2015).

75. 75.

Chen, F. et al. Engineering of Hollow Mesoporous Silica Nanoparticles for Remarkably Enhanced Tumor Active Targeting Efficacy. Scientific Reports 4, 5080 (2014).

76. 76.

Peng, M. et al. Dextran-coated superparamagnetic nanoparticles as potential cancer drug carriers in vivo. Nanoscale 7, 11155–11162 (2015).

77. 77.

Huang, Y., Mao, K., Zhang, B. & Zhao, Y. Superparamagnetic iron oxide nanoparticles conjugated with folic acid for dual target-specific drug delivery and MRI in cancer theranostics. Mater. Sci. Eng. C 70, 763–771 (2017).

78. 78.

Yu, M. K. et al. Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew. Chem., Int. Ed. 47, 5362–5365 (2008).

79. 79.

Mjos, K. D., Cawthray, J. F., Jamieson, G., Fox, J. A. & Orvig, C. Iron(iii)-binding of the anticancer agents doxorubicin and vosaroxin. Dalton Transactions 44, 2348–2358 (2015).

80. 80.

Gai, S. et al. Fibrous-structured magnetic and mesoporous Fe3O4/silica microspheres: synthesis and intracellular doxorubicin delivery. J. Mater. Chem. 21, 16420–16426 (2011).

81. 81.

Ali, R. et al. Isolation and characterization of a new naturally immortalized human breast carcinoma cell line, KAIMRC1. BMC Cancer 17, 803 (2017).

82. 82.

Chaves, N. L. et al. Exploring cellular uptake of iron oxide nanoparticles associated with rhodium citrate in breast cancer cells. Int. J. Nanomedicine 12, 5511–5523 (2017).

83. 83.

Kohler, N., Sun, C. & Wang, J. & Zhang, M. Methotrexate-Modified Superparamagnetic Nanoparticles and Their Intracellular Uptake into Human. Cancer Cells. Langmuir 21, 8858–8864 (2005).

84. 84.

Kettler, K., Veltman, K., van de Meent, D., van Wezel, A. & Hendriks, A. J. Cellular uptake of nanoparticles as determined by particle properties, experimental conditions, and cell type. Environ. Toxicol. Chem. 33, 481–492 (2014).

85. 85.

Holliday, D. L. & Speirs, V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 13, 215–215 (2011).

86. 86.

Al-Salam, S. et al. In Vitro Study and Biocompatibility of Calcined Mesoporous Silica Microparticles in Mouse Lung. Toxicol. Sci. 122, 86–99 (2011).

87. 87.

Blumen, S. R. et al. Unique uptake of acid-prepared mesoporous spheres by lung epithelial and mesothelioma cells. Am J Respir Cell Mol Biol 36, 333–342 (2007).

88. 88.

Bareford, L. M. & Swaan, P. W. Endocytic mechanisms for targeted drug delivery. Advanced drug delivery reviews 59, 748–758 (2007).

89. 89.

Shang, L., Nienhaus, K. & Nienhaus, G. U. Engineered nanoparticles interacting with cells: size matters. J. Nanobiotechnology 12, 5–5 (2014).

90. 90.

Gratton, S. E. A. et al. The effect of particle design on cellular internalization pathways. Proc. Natl. Acad. Sci. USA 105, 11613–11618 (2008).

91. 91.

Rejman, J., Oberle, V., Zuhorn, I. S. & Hoekstra, D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem. J. 377, 159–169 (2004).

92. 92.

Chaudhury, S., Varadachari, C. & Ghosh, K. Ab Initio Studies on Hematite Surface and the Adsorption of Phosphate. J. Theor. Chem. 2014, 7 (2014).

93. 93.

Palm, W. Metabolic functions of macropinocytosis. Philos Trans R Soc Lond B Biol Sci 374, 20180285 (2019).

94. 94.

Nel, A., Xia, T., Mädler, L. & Li, N. Toxic Potential of Materials at the Nanolevel. Science 311, 622 (2006).

95. 95.

Saggar, J. K., Yu, M., Tan, Q. & Tannock, I. F. The Tumor Microenvironment and Strategies to Improve Drug Distribution. Front. Oncol. 3 (2013).

96. 96.

Danhier, F., Feron, O. & Préat, V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control Release 148, 135–146 (2010).

97. 97.

Torchilin, V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 63, 131–135 (2011).

98. 98.

Minchinton, A. I. & Tannock, I. F. Drug penetration in solid tumours. Nat. Rev. Cancer 6, 583–592 (2006).

99. 99.

Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).

100. 100.

Li, S.-D. & Huang, L. Pharmacokinetics and Biodistribution of Nanoparticles. Mol. Pharmaceutics 5, 496–504 (2008).

101. 101.

Hashizume, H. et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156, 1363–1380 (2000).

102. 102.

Sarin, H. et al. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J. Transl. Med. 7, 51 (2009).

103. 103.

Hillegass, J. M. et al. Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy. Int. J. Cancer 129, 233–244 (2011).

104. 104.

Li, Z. et al. Biomimetic nanoassembly for targeted antigen delivery and enhanced Th1-type immune response. Chem. Commun. 51, 15975–15978 (2015).

## Acknowledgements

This work was funded by KAIMRC under grant RC13/204 and RC16/096. The authors acknowledge the continuous support by KSAU-HS, NGHA, the core facility, and the Nanomedicine Department at KAIMRC. The authors also thank the pre-med undergraduate student Sulaiman M.S. Alhumaid (synthesis of particles), Omar Baz (tissue preparation), Nosaibah Samman (KAIMRC1 isolation), AlShaima AlHallaj (cell culture), and Dr. Lolwah AbdullahAlRiyees (breast cancer surgery) for their assistance and help in the study as indicated.

## Author information

Authors

### Contributions

K.H.B. and R.A. contributed equally. K.H.B. conceived and designed the study. K.H.B. prepared all the particles and performed their characterization. R.A. conceived the biological part, performed confocal imaging and electron microscopy. H.Z. prepared and cultured the cells. T.T. conducted the flow cytometry experiments. A.H.A. performed the TEM cellular images. A.L.K. contributed to breast tumor tissue experiments. M.B. facilitated the use of the core facility. A.K. supervised and contributed to revisions. K.H.B. analyzed the experimental data and wrote the manuscript. R.A. helped in the biological part of the manuscript preparation. All authors reviewed and approved the manuscript.

### Corresponding author

Correspondence to Kheireddine El-Boubbou.

## Ethics declarations

### Competing Interests

The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Supplementary information

### 41598_2019_46007_MOESM1_ESM.docx

Preparation of iron oxide mesoporous magnetic microparticles as novel multidrug carriers for synergistic anticancer therapy and deep tumor penetration

## Rights and permissions

Reprints and Permissions

El-Boubbou, K., Ali, R., Al-Zahrani, H. et al. Preparation of iron oxide mesoporous magnetic microparticles as novel multidrug carriers for synergistic anticancer therapy and deep tumor penetration. Sci Rep 9, 9481 (2019). https://doi.org/10.1038/s41598-019-46007-z

• Accepted:

• Published:

• ### Recent advances in porous nanostructures for cancer theranostics

• Jinping Wang
• , Beilu Zhang
• , Jingyu Sun
• , Wei Hu
•  & Hongjun Wang

Nano Today (2021)

• ### Advances in regulating physicochemical properties of mesoporous silica nanocarriers to overcome biological barriers

• Yumei Wang
• , Kaijun Gou
• , Xianmou Guo
• , Jia Ke
• , Sanming Li
•  & Heran Li

Acta Biomaterialia (2021)

• ### Mesoporous iron oxide nanoparticles loaded with ciprofloxacin as a potential biocompatible antibacterial system

• Wivyan Castro Lage
• , Daniela Sachs
• , Tainara Aparecida Nunes Ribeiro
• , Marli Luiza Tebaldi
• , Yanka dos Reis Soares de Moura
• , Stephanie Calazans Domingues
•  & Daniel Cristian Ferreira Soares

Microporous and Mesoporous Materials (2021)

• ### Iron Oxide Mesoporous Magnetic Nanostructures with High Surface Area for Enhanced and Selective Drug Delivery to Metastatic Cancer Cells

• Kheireddine El-Boubbou
• , Rizwan Ali
• , Sulaiman Al-Humaid
• , Alshaimaa Alhallaj
• , O. Lemine
• , Mohamed Boudjelal
•  & Abdulmohsen AlKushi

Pharmaceutics (2021)

• ### One-pot green synthesis of iron oxide nanoparticles from Bauhinia tomentosa: Characterization and application towards synthesis of 1, 3 diolein

• Sushmitha Lakshmnarayanan
• , M. Furhana Shereen
• , K. L. Niraimathi
• , P. Brindha
•  & A. Arumugam

Scientific Reports (2021)